Workflow
防粘连及止血产品
icon
Search documents
昊海生科股价微跌0.19% 半年报显示营收净利双降
Sou Hu Cai Jing· 2025-08-22 15:07
Group 1 - The core viewpoint of the article highlights the financial performance and stock market activity of Haohai Biological Technology, indicating a decline in revenue and net profit for the first half of 2025 compared to the previous year [1] - On August 22, Haohai Biological's stock closed at 57.48 yuan, down 0.19% from the previous trading day, with a trading volume of 11,747 hands and a transaction amount of 0.67 billion yuan [1] - The company's total market capitalization is 133.69 billion yuan, with a price-to-earnings ratio of 31.67 times [1] Group 2 - According to the latest semi-annual report, the company achieved operating revenue of 1.304 billion yuan in the first half of 2025, a year-on-year decrease of 7.12%, and a net profit attributable to shareholders of 211 million yuan, down 10.29% year-on-year [1] - The second quarter showed a more pronounced decline, with revenue down 9.6% and net profit down 12.3% year-on-year [1] - By business segment, revenue from medical beauty and wound care products decreased by 16.8%, and revenue from ophthalmic products fell by 18.61%, while revenue from anti-adhesion and hemostatic products grew by 59.61% [1] Group 3 - The company announced a cash dividend of 4 yuan per 10 shares, with a total distribution amount expected to be 91.49 million yuan [1]
26.98亿!昊海生科发布最新年报
思宇MedTech· 2025-03-24 03:42
合作伙伴征集:2025全球手术机器人大会 报名:首届全球骨科大会 | 奖项评选 2025年3月22日, 昊海生科 发布了2024年年报。 # 财报数据 # 关于昊海生科 报名:首届全球眼科大会 | 名额有限 报名:首届全球心血管大会 | 奖项申报 2024年营业收入 26.98亿 元,同比增长1.64%; 归母净利润4.20亿元,同比增长1.04%;扣非归母净 利润3.79亿元,同比下滑1.12%。 2024Q4营业收入 6.23亿 元,同比下滑7.35%,环比增长9.74%; 归母净利润0.80亿元,同比下降 10.93%;扣非归母净利润0.58亿元,同比下滑26.83%。 分产品:2024年医疗美容与创面护理产品收入11.95亿元,同比增长13.08%,其中玻尿酸产品收入 7.42亿元,同比增长23.23%;眼科产品收入8.58亿元,同比下降7.60%;骨科产品收入4.57亿元,同 比下降4.11%;防粘连及止血产品1.46亿元,同比下降0.58%;其他产品收入0.38亿元,同比增长 1.56%。 2024 年公司整体毛利率为 69.89%,与上年度的 70.46%相比略有下降,其中,医美玻尿酸产品收入 ...